Clinical Trial Update: A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Clinical update on a Phase 1/Phase 2 study of mRNA-2808 in participants with relapsed or refractory multiple myeloma; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• mRNA-2808

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING